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DOI 10.1016/j.ccr.2011.05.027SUMMARYTo metastasize, a tumor cell must acquire abilities such as the capacity to colonize new tissue and evade
immune surveillance. Recent evidence suggests that microRNAs can promote the evolution of malignant
behaviors by regulating multiple targets. We performed a microRNA analysis of human melanoma, a highly
invasive cancer, and found thatmiR-30b/30d upregulation correlateswith stage,metastatic potential, shorter
time to recurrence, and reduced overall survival. Ectopic expression of miR-30b/30d promoted the meta-
static behavior of melanoma cells by directly targeting the GalNAc transferase GALNT7, resulted in increased
synthesis of the immunosuppressive cytokine IL-10, and reduced immune cell activation and recruitment.
These data support a key role of miR-30b/30d and GalNAc transferases in metastasis, by simultaneously
promoting cellular invasion and immunosuppression.INTRODUCTION
Far more attention has been given to the process of malignant
transformation than to metastasis, yet it is the spread of trans-
formed cells that accounts for 90% of deaths from solid tumors
(Gupta and Massague´, 2006). The capacity of a tumor cell to
metastasize depends upon its ability to escape the primary
tumor, intravasate into circulation, survive transit, extravasate
into distant tissue, and colonize it, while evading immune surveil-Significance
microRNAs are emerging as key contributors to tumor metast
thereby alter several functions simultaneously. We found a
enhancing invasive capabilities of melanoma cells and suppre
cells to migrate and invade foreign tissue. Both these effects of
transferases. Aberrant glycosylation has previously been con
mechanisms and their impact on specific cellular pathways are
ation as a molecular link between tumor cell migration and imm
metastasis.
104 Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc.lance and promoting various changes to the local tissue environ-
ment (Gupta and Massague´, 2006). The conventional view of
tumor progression assumed that malignant cells evolve these
aggressive functions over time, but we are beginning to appre-
ciate that metastatic traits may be acquired earlier rather
than later in oncogenesis (Gupta et al., 2005; Scheel et al.,
2007; Talmadge, 2007).
Accumulating evidence suggests that alterations in micro-
RNA (miRNA) expression might prove crucial in promotingasis because of their ability to regulate multiple targets and
miRNA cluster that promotes metastasis by concurrently
ssing immune surveillance mechanisms, allowing the tumor
miR-30b/30d are mediated by direct suppression of GalNAc
nected to tumor progression, but the underlying molecular
poorly understood. Our work places the control of glycosyl-
une evasion, two processes that act synergistically during
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Figure 1. High miR-30b and miR-30d Levels Are Associated with Metastatic Behavior, Shorter Time to Recurrence, and Lower Overall
Survival in Melanoma
(A) Increased relative levels ofmiR-30b andmiR-30d in 17 metastatic cases compared to the levels in their matched primary tumors, as measured by qRT-PCR.
(B and C) miR-30b and miR-30d normalized array levels in 92 primary cases with (B) increased thickness and (C) increased stage. ANOVA test was applied
in (B).
(D) miR-30b and miR-30d normalized array levels in superficial spreading melanoma (SSM) (n = 28) versus nodular melanoma (n = 56).
(E and F) Curves show shorter time to recurrence (E) and lower overall survival (F; n = 92) in patients with high (above median value) versus low (below median
value) miR-30b/30d levels. (*p < 0.05; **p < 0.01; ***p < 0.001).
See also Figure S1 and Table S1.
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miR-30b/d Promote Metastasis by Targeting GALNT7metastasis (Croce and Calin, 2005; Ma et al., 2007, 2010;
Tavazoie et al., 2008). This is an intuitively compelling idea
because miRNAs have been found to serve important regula-
tory functions during numerous developmental and patholog-
ical processes by altering multiple target genes and, there-
fore, multiple cellular activities, simultaneously (Gupta and
Massague´, 2006). Expression profiling has identified miRNA
signatures for a number of tumors that correlate with disease
stage and clinical outcome (Calin and Croce, 2006). The
extent to which these alterations in miRNA expression actu-
ally influence metastasis is difficult to decipher because in
many cases the miRNAs exert confounding effects on cell
growth and proliferation within the primary tumor (Tavazoie
et al., 2008). Given both the importance of metastasis to
cancer-associated lethality and our relatively tenuous grasp
of how it is executed by tumor cells, we sought to investigate
the role of miRNAs in one of the most invasive tumor types,
melanoma.RESULTS
Expression ofmiR-30b and 30d in Human Melanoma
Marks the Progression from Primary to Metastatic
Tumors
miRNA array analysis of 59 metastatic melanoma tumor
samples (Segura et al., 2010), followed by quantitative RT-PCR
(qRT-PCR) validation, revealed relatively high expression levels
of miR-30b and -30d. These two miRNAs form a cluster on
8q24, a common amplicon in melanoma (Ehlers et al., 2005).
No statistically significant upregulation of miR-30b/30d was
observed from congenital nevi to primary melanomas (see Fig-
ure S1A available online). However, in a subset of 17 paired
samples (primary tumor and ametastasis from the same patient),
we found a statistically significant increase in expression of
these miRNAs from the primary to the metastatic stage (p =
0.0007 formiR-30b; p = 0.026 formiR-30d) (Figure 1A). A miRNA
profile of primary melanomas (n = 92; Table S1) revealed thatCancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc. 105
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miR-30b/d Promote Metastasis by Targeting GALNT7higher levels of miR-30b and -30d correlated with increased
tumor thickness (p = 0.002 formiR-30b, p = 0.0002 for 30d) (Fig-
ure 1B) and advancing stage (I–III) (p = 0.004 for miR-30b, p =
0.001 for 30d; Figure 1C), suggesting an association between
miR-30b/d expression and tumor progression. By histological
subtype the more invasive nodular melanomas had higher
miR-30b/30d levels than superficial spreading melanomas
(SSMs) (p = 0.015 for miR-30b, p = 0.0189 for 30d) (Figure 1D).
Furthermore, the subgroup of primary melanomas that had
metastasized (n = 44) showed higher levels ofmiR-30b and -30d
expression than those that had not spread (n = 48) during
a period of 24 months or more of follow-up (p = 0.048 for miR-
30b, p = 0.037 for miR-30d; data not shown). Accordingly,
miR-30b and miR-30d levels above the median correlated with
shorter time to recurrence (p = 0.04 for miR-30b and p = 0.01
for miR-30d) (Figure 1E) and lower overall survival of patients
with melanoma (p = 0.0004 for miR-30b and p = 0.02 for miR-
30d) (Figure 1F). Multivariate analysis using COXPHmodels indi-
cated that the expression level ofmiR-30d is a statistically signif-
icant independent predictor for melanoma mortality (p = 0.004)
when adjusted for primary tumor thickness and ulceration
status. The expression level of miR-30b is only marginally
significant as an independent predictor for death with mela-
noma when adjusted for primary tumor thickness and ulcera-
tion (p = 0.054). These data support an association between
miR-30b/30d upregulation and increased melanoma aggres-
siveness, and suggest a potential use of these miRNAs as pro-
gnostic biomarkers.
miR-30b/30d Overexpression Correlates with Genomic
Amplification in a Subset of Human Melanoma Samples
The miR-30b/30d cluster (8q24.22–8q24.23) is located in the
vicinity of a genomic region containing the oncogene c-MYC
(8q24.21), which is frequently amplified in multiple cancer types,
including: medulloblastoma (Lu et al., 2009); uveal melanoma
(Ehlers et al., 2005); head, neck, and cervical squamous cell
carcinomas; and bladder (Visapa¨a¨ et al., 2003), lung, and pros-
tate cancer (Van Den Berg et al., 1995). c-MYC amplification is
usually associated with tumor progression.
We found the miR-30b/30d genomic region amplified in
12 out of 33 metastatic melanoma tissues (36.4% of cases, Fig-
ure S1B), of which approximately half harbored concomitant
c-MYC gene copy gains (Figure S1C), suggesting that the miR-
30b/30d gains are generally independent of c-MYC amplifica-
tion. Interestingly, we noted that a higher fraction of patients
carrying the miR-30b/30d amplification died within the study
period (Figure S1B), suggesting that this genetic trait is associ-
ated with more aggressive disease.
miR-30b ormiR-30d Modulation Alters the Invasive
Potential of Melanoma Cells without Affecting Cell
Proliferation
Because upregulation of miR-30b and 30d is associated with
progression from primary to metastatic melanoma, we asked
whether these miRNAs enhance the invasive behavior of mela-
noma cells. Using a fibronectin transwell invasion assay, we
found that ectopic expression of miR-30b and 30d (Figure S2A)
strongly stimulated the invasive capacity of two metastatic
melanoma cell lines, 113/6-4L (hereafter, 4L) and 131/4-5B1106 Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc.(hereafter 5B1) (Cruz-Munoz et al., 2008) (Figure 2A) (p = 0.037
and p = 0.0002 for miR-30b and p = 0.009 and p = 0.011 for
miR-30d in 4L and 5B1, respectively). In contrast, silencing of
miR-30b or miR-30d by antisense oligonucleotide (anti-miR)
transfection (Figure S2A) suppressed cell migration (p = 0.026
and p = 0.032 for miR-30b; p = 0.041 and p = 0.044 for miR-
30d in 4L and 5B1, respectively) (Figure 2A).
To determine whether the increase in invasive behavior could
be explained, at least in part, by increased cell proliferation, we
compared the growth rates of cells transduced with miR-30b
or miR-30d or scrambled control. We found no statistically
significant differences by means of trypan blue exclusion or
crystal violet staining (data not shown). Therefore, we conclude
that miR-30b/30d increase melanoma cells’ capacity to mi-
grate through the extracellular matrix, an essential ability for
metastasis.
Next, because miR-30b and miR-30d are coexpressed from
the same cluster, we tested the effect of introducing both simul-
taneously. Neither additive nor synergistic effects were detected
in the Boyden chamber assay (Figure 2A), indicating that the two
miRNAs have redundant proinvasive functions. This is not
surprising because they share the same seed region and, thus,
likely operate through common targets.
miR-30b/30d Overexpression Enhances Metastasis,
WhereasmiR-30d’s Silencing Represses Metastasis
In Vivo
Our in vitro results led us to study the impact of miR-30d
downregulation in a classic in vivo model of lung metastasis:
we transiently transduced B16F10 mouse melanoma cells
in vitro with scrambled or anti-miR-30d oligonucleotides (Fig-
ure S2B) and injected them into the tail veins of immunocompe-
tent mice 8–weeks of age. Eleven days postinjection, we sacri-
ficed the mice and dissected the lungs for macroscopic and
microscopic histology. Lungs of B16F10/anti-miR-30d-injected
mice harbored significantly fewer microscopic and macro-
scopic metastases than scrambled control (p = 0.0085) (Fig-
ure 2B). Conversely, mice injected with B16F10 cells transiently
transduced with miR-30d mimic oligonucleotides generated
more metastatic foci than control cells transfected with scram-
bled oligonucleotide (p = 0.0218) (Figure 2C). Then, we com-
pared the metastatic potential of B16 transiently transfected
with miR-30b, miR-30d, or combinations of miR-30b and 30d
mimic oligonucleotides, injected through the tail vein. miR-30d
and miR-30b had similar prometastatic effects, and the combi-
nation of the two showed only a slight increase over miR-30d
alone (Figures S3A–S3C). Therefore, both our in vitro and
in vivo results indicate that miR-30b and miR-30d have redun-
dant effects on invasion and metastasis. Given this functional
redundancy, we focused primarily on miR-30d in the following
experiments.
We asked whether miR-30d could confer metastatic potential
to melanoma cells significantly less invasive, such as the primary
melanoma cells WM35 and WM98. In vitro invasion assays
revealed that ectopic expression of miR-30d dramatically
enhanced the invasive capacity of WM35 and WM98 primary
human melanoma cells (p < 0.001 for both cell lines) (Figure 2D).
In vivo,WM98 cells display very poor seeding and colonization of
mouse lungs upon tail vein injection, but miR-30d upregulation
Figure 2. miR-30b and miR-30d Promote Melanoma Invasion and Metastasis In Vitro and In Vivo
(A) Transwell invasion assay of indicated cell lines with miR-30b, -30d, or both, either silenced or overexpressed (mean ± SEM). scr, scrambled control.
(B and C) In vivometastasis assay with B16F10mousemelanoma cells transfected with scr, anti-miR-30d, ormiR-30dmimics injected through the lateral tail vein
of C57BL/6J mice. Histogram in (B) shows that anti-miR-30d suppressedmetastasis, whereasmiR-30d increased the metastatic behavior (C) (mean ± SEM). On
the right are macroscopic pictures of mouse lungs and H&E sections of lung metastases at termination of the experiment. Black dotted circles mark
metastatic foci.
(D) Transwell invasion assay with primary melanoma cell lines WM98 and WM35 transduced with scr or miR-30d (mean ± SEM).
(E) In vivometastasis assaywithWM98melanoma cells stably transducedwithGIPZ-scr or GIPZ-miR-30d injected through the lateral tail vein of NOG/SCIDmice.
Histogram shows the percentage of mice that developed lung metastases in each cohort. Whisker plots show the distribution of the number of metastases per
section. Representative H&E sections of lungs are shown. Black dotted circles mark metastatic foci.
(F–H) Preclinical model of human melanoma metastasis. 5B1 cells stably transduced with either scr or miR-30d vectors were injected subcutaneously into the
flanks of NOG/SCID mice.
(F) H&E sections show increased local invasion ofmiR-30d-transduced tumors. Histogram represents the percentage of mice in each cohort with primary tumors
that invaded grossly into the leg. M, muscle; T, tumor.
(G and H) Representative micrographs of H&E sections of lungs (G) or livers (H) are presented. Histograms depict the percentage of mice that developed lung or
liver metastases in each cohort. Whisker plots show the distribution of the number or size (largest in each section) of metastasis per section. Error bars represent
the median value (*p < 0.05; **p < 0.01; ***p < 0.001). For all micrographs scale bars represent 100 mm.
See also Figure S2.
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miR-30b/d Promote Metastasis by Targeting GALNT7dramatically increased both the incidence of lung metastasis
and the total number of micrometastasis per lung section (Fig-
ure 2E). These in vitro and in vivo results evidence the strong
prometastatic potential of this miRNA.
Given the limitations of the tail vein injection models at reca-
pitulating all the steps of metastasis, we decided to test the
effects of miR-30d in a more preclinical system, in whichhuman melanoma cells are injected in the flanks of immuno-
compromised mice. These mice form a tumor mass within
about 2 weeks, from which cells migrate and reach the lungs
in 8–10 weeks with occasional spread to the liver and other
organs (Cruz-Munoz et al., 2008). 5B1 cells stably transduced
with lentiviruses carrying pre-miR-30d (GIPZ/miR-30d) or a
scrambled sequence (GIPZ/scr) were inoculated in the flanksCancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc. 107
GALNT7 GALNT1 SEMA3A CELSR3 TWF1 ITGA6 FAP SOCS1 HDAC9
0.0
0.5
1.0
1.5
scr (50nM)
30b (50nM)
30d (50nM)
******
** **
* *
******
******
Lu
ci
fe
ra
se
 v
al
ue
s 
(a
.u
.)
3'UTR
0.0
0.5
1.0
1.5
GALNT7 
scr 30b 30d
*
**
*
*
**
***
**
* * **
***
GALNT1 
scr 30b 30d
SEMA3A
scr 30b 30d
CELSR3
scr 30b 30d
TWF1
scr 30b 30d
***
***
***
***
0.5nM
5nM
Oligo
Lu
ci
fe
ra
se
 v
al
ue
s 
(a
.u
.)
B C
E
Cell-Cell/ECM
contacts
Motility/
Metastasis
Immune 
response/
Angiogenesis
Down-regulated 
genes (4L)
Down-regulated 
genes (5B1)
4L 5B1 4L 5B1
scr 30d
Predicted 30d targets
 (TargetScan)
FNDC1 
COL4A1 
COL4A5 
ADAMTS17 
FAP 
ITGA6 
GALNT1 
GALNT7 
RHOJ 
ZEB1 
FZD7 
CTNNB1 
CTNNBIP1 
GNAI2 
TWF1 
MMP8 
Down-regulated 
genes (4L)
Down-regulated 
genes (5B1)
Predicted targets of a random miRNA
 (TargetScan)
F
889 
117 155 
1
4 5
57 
2853 
89 112 
29 
47 33 
29 
A
D
GALNT7 
GALNT1 
SEMA3A 
CELSR3 
ITGA6 
FAP 
SOCS1 
HDAC9 
GNAI2 
miR-30d levels
0 1 2
IL10 
CTLA4 
EGF 
IL27RA  
CCR1  
SEMA3A 
CCL20 
G H
0.5 1 2
GALNT7 
3’ UTR: 5’ -…UCAUCUGCAGUUACUGUUUACA……UAAACUUUGUAGAUGUUUACA…- 3’ 
Mut 1: 5’ -…UCAUCUGCAGUUACUGAUAUCA……UAAACUUUGUAGAUGUUUACA…- 3’  
 Mut 2: 5’ -…UCAUCUGCAGUUACUGUUUACA……UAAACUUUGUAGAUGGGCCCA…- 3’  
GALNT1 
3’ UTR: 5’ -…ACUGUGCACACUGAUGUUUACA…- 3’ 
Mut: 5’ -…ACUGUGCACACUGAUGAUAUCA…- 3’   
SEMA3A 
3’ UTR: 5’ -…GGCAUUAUGUGGA-UGUUUACA…- 3’ 
Mut: 5’ -…GGCAUUAUGUGGA-UGAUAUCA…- 3’   
+171 +192 +208 +228 
+214 +235 
+90 +110 0.0
0.5
1.0
1.5
Construct: wt wt mut1mut2 DM wt mutwt wt mut
Oligo: scr 30b 30d scr 30b 30d
GALNT7
wt mut1mut2 DM
SEMA3A
*** ***
***
**
***
***
**
*
wt mutwt wt mut
scr 30b 30d
GALNT1
**
***
Lu
ci
fe
ra
se
 v
al
ue
s 
(a
.u
.)
Figure 3. miR-30b/30d Directly Target SEMA3A, TWF1, CESLR3, GALNT7, and GALNT1
(A–C) Microarray analysis performed in independent biological duplicates for each indicated cell line.
(A) Heat map showing the average normalized relative expression levels of genes involved in cell-cell/ECM contacts, motility, metastasis, immune response, or
angiogenesis in the indicated cell lines transfected with either scr or miR-30d mimics.
(B) Venn diagram depicting the overlap between predicted miR-30d targets (TargetScan) and probes significantly downregulated in response to miR-30d
overexpression in two cell lines.
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miR-30b/d Promote Metastasis by Targeting GALNT7of NOD/Shi-scid/IL-2Rgnul (NOG/SCID) mice. Local muscle
invasion involving the proximal leg was more commonly found
among the GIPZ/miR-30d-injected mice than in the GIPZ/scr
group (Figure 2F). Moreover, the proportion of mice that devel-
oped liver metastases at completion of the experiment was
higher in the miR-30d cohort (9 of 19) than in the scramble
cohort (3 of 19) (Figure 2H) (p = 0.038). Both the number and
size of lung and liver micrometastases found 11 weeks after
the initial injection were elevated in mice of the GIPZ/miR-30d
cohort (Figures 2G and 2H). These data demonstrate that
miR-30d augments the ability of melanoma cells to intravasate,
extravasate, seed, and/or colonize a distant site.
GALNT7, GALNT1, SEMA3, CELSR3, and TWF1 Are
miR-30b/30d Targets in Melanoma Cells
To identify cellular pathways modulated by miR-30d upregula-
tion and to define specific gene targets that might mediate its
prometastatic effects, we conducted a global transcriptome
analysis of 4L and 5B1 cells transduced withmiR-30d or scram-
bled oligonucleotides using Affymetrix arrays. Using thresholds
of a minimum fold change of 1.33 and a p value of <0.05, we
found 784 genes to be differentially expressed by the 2 cell lines.
Gene ontology analysis revealed candidate genes whose altered
expression could contribute to the invasive phenotype induced
by miR-30d (Figure 3A). Of the 784 altered genes, we found
217 genes downregulated in 4L, 180 downregulated in 5B1,
and 58 downregulated in both lines. Nearly one-third of the
downregulated genes were direct miR-30d targets predicted
by public algorithms (TargetScan) (Lewis et al., 2005) (Figure 3B),
and included GNAI2, a validated miR-30d target (Yao et al.,
2010). Meanwhile, the overlap with targets of a randomly
selected miRNA was minimal (Figure 3C). Interestingly, data
mining of our previously publishedmRNA profile of humanmeta-
static melanoma tissues (Bogunovic et al., 2009) revealed that
miR-30d levels inversely correlate with expression of several
targets identified in our array analysis, including SEMA3A,
GALNT1, and GALNT7 (Figure 3D), further supporting the phys-
iological relevance of this regulatory mechanism. The expression
levels of other GALNT family members, many of which carry
recognition sites for miR-30d in their 30 untranslated regions
(UTRs), also inversely correlated with miR-30d levels in those
tissues (Figure S4). Using 30UTR luciferase reporter assays and
qRT-PCR, we confirmed that GALNT7, GALNT1, SEMA3,
CESLR3, and TWF1 are direct targets of miR-30b/30d (Figures
3E and 3F). Mutations in the miRNA recognition sites (Figure 3G)
rendered the constructs unresponsive to miR-30b or miR-30d
induction (Figure 3H), further confirming that these are direct
miR-30b/30d targets.(C) Venn diagram illustrating the overlap between predicted targets of an unrela
to miR-30d overexpression in two cell lines.
(D) Heat map depicting the expression levels of selected predicted targets in 18
column represents an average expression of four to eight samples with similar m
(E) Reporter assay in 293T cells transfected with miR-30b or miR-30d and cons
targets (mean ± SEM).
(F) Reporter assay in 293T cells transfected with luciferase constructs fused to th
lower concentrations of miR-30b/30d (mean ± SEM).
(G and H) Reporter assay in 293T cells transfected with luciferase constructs carry
sites. DM, double mutant (mean ± SEM). (*p < 0.05; **p < 0.01; ***p < 0.001).GALNT7 Is a Critical Mediator ofmiR-30d Proinvasive
Effects In Vitro and Prometastatic Behavior In Vivo
Next, we investigated which, if any, miR-30d direct targets
mediate the capacity for cellular invasion. Several candidates
seemed appealing: CELSR3 is involved in contact-mediated
cell-to-cell communication (Wu and Maniatis, 1999); TWF1
encodes for twinfilin (Palmgren et al., 2002), which regulates
cell motility; and Semaphorin 3A (SEMA3A) exerts antiangio-
genic properties (Maione et al., 2009). GalNAc transferases (Gal-
NAc-Ts) initiate mucin-type O-linked glycosylation in the Golgi
apparatus by catalyzing the transfer of N-acetylgalactosamine
(GalNAc) to serine and threonine residues on target proteins.
These posttranslational modifications affect the structure of
numerous transmembranal substrates, determining their func-
tional interaction with the extracellular environment (Ten Hagen
et al., 2003).
Given their described roles, all these molecules seemed plau-
sible candidates to shape the prometastatic influence of miR-
30b/30d. To determine whether any of them were critical media-
tors of miR-30d’s role in cellular invasion, we silenced each of
them using RNA interference (RNAi) in melanoma cell lines.
Although downregulating SEMA3A, CELSR3, and TWF1 did
not enhance invasion, repression of GALNT7, and to a lesser
extent GALNT1, recapitulated the proinvasive effects of miR-
30d (p < 0.0001 for GALNT7; p = 0.004 for 5B1 and 0.01 for
A375 for GALNT1) (Figure 4A; Figure S2C). Moreover, coexpres-
sion of a GALNT7 cDNA lacking the 30UTR was able to suppress
miR-30d promotion of cell invasion, indicating that GALNT7
silencing critically mediates miR-30d’s promigratory effects in
melanoma (p < 0.0001) (Figure 4B; Figure S2D).
GALNT7 silencing by siRNA oligonucleotides was able to
mirror miR-30d’s promotion of B16F10 metastatic capacity
upon tail vein injection (p = 0.0006) (Figure 4C). Finally, we
compared the metastatic potential of B16F10 cells transduced
with miR-30d oligonucleotides and either an empty lentiviral
vector or one expressing the murine GALNT7 cDNA. Concomi-
tant ectopic expression of GALNT7 and miR-30d interfered
with miR-30d’s prometastatic effect (p = 0.0002) (Figure 4D).
Overall, our in vitro and in vivo data support GALNT7 inhibition
as a key contributor of miR-30d’s prometastatic effects in
melanoma cells.
miR-30d Overexpression and GALNT7 Inhibition
Produce Similar Glycomic Changes, which Are Rescued
by GALNT7 Ectopic Expression
We hypothesized that inhibiting GALNT7 could promote cell
invasion bymodifying the O-glycosylation patterns of membrane
proteins that interact with the extracellular matrix and cells of theted miRNA (miR-199a-3p) and genes significantly downregulated in response
human metastatic melanoma tissues with increasing levels of miR-30d. Each
iR-30d levels. See also Figure S4.
tructs carrying the luciferase cDNA fused to the 30UTR of selected predicted
e 30UTR of GALNT7, GALNT1, SEMA3A, CESLR3, and TWF1 and significantly
ingGALNT7,GALNT1, and SEMA3A 30UTRs mutated inmiR-30b/30d-binding
Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc. 109
A B
4L 5B1 A375
0
1
2
3
4
siGALNT7
30d 
scr 
siGALNT1
***
***
***
*** ** *** *** *
*
R
el
at
iv
e 
in
va
si
on
0
1
2
3
4
******
******
30d+GALNT7
scr 
30d
GALNT7 
******
R
el
at
iv
e 
 in
va
si
on
 
5B1 A3754L
sc
r 
30
d 
siG
AL
NT
7
0.0
0.5
1.0
1.5
2.0 ***
***
R
el
at
iv
e 
# 
of
 m
et
as
ta
si
s
scr 30d siGALNT7
em
pty
+s
cr
em
pty
+3
0d
GA
LN
T7
+3
0d
GA
LN
T7
+s
cr
0.0
0.5
1.0
1.5
2.0
*** ***
R
el
at
iv
e 
# 
of
 m
et
as
ta
si
s
empty+scr empty+30d GALNT7+scrGALNT7+30d
C
D
30d GALNT7
0
1
2
3
600
800
1000
1200
scr 
30d 
siGALNT7
R
el
at
iv
e 
G
en
e 
Ex
pr
es
si
on
30d GALNT7
0
1
2
3
100
200
300
400 empty+scr
empty+30d
GALNT7+30d
GALNT7+scr
R
el
at
iv
e 
G
en
e 
Ex
pr
es
si
on
Figure 4. GALNT7 Modulation Accounts for miR-30d Proinvasive Effects In Vitro and In Vivo
(A and B) Transwell invasion assay of indicated cell lines transfected with scr, miR-30d, siGALNT7, siGALNT1, GALNT7 cDNA, or cotransfected with miR-30d
and GALNT7 cDNA (mean ± SEM).
(C and D) In vivo metastasis assay with B16F10 mouse melanoma cells.
(C) Cells were transfected with scr, miR-30d mimics, or siGALNT7 oligos and injected through the lateral tail vein of C57BL/6J mice. Levels of knockdown or
overexpression are shown on the left. Histogram and macroscopic pictures are shown.
(D) Cells were stably transduced with either pEIGW-Empty or pEIGW-mmuGALNT7. Twenty-four hours prior to injection, cells were transfected with either scr
control ormiR-30d oligonucleotides. Cells were injected through the lateral tail vein of NOG/SCIDmice. Levels of overexpression are shown on the left. Histogram
and representative macroscopic pictures are depicted (mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001).
See also Figure S3.
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glycomic profiles of melanoma cells transfected with miR-
30d only, siGALNT7 only, miR-30d together with GALNT7
cDNA, and scrambled-control miRNA, using lectin micro-
arrays consisting of 84 discrete carbohydrate-binding proteins
(Krishnamoorthy et al., 2009). We analyzed cellular micellae
from isolated cell membranes, which previous work has shown
to contain both glycoproteins and glycolipids representative of
the cell surface (Pilobello et al., 2005). Our lectin microarray
analysis revealed an overall decrease in glycosylation in both
siGALNT7 and miR30d-transduced cells relative to scrambled
control, affecting both N- and O-linked glycosylation (Figure S5).
The most pronounced conserved effects across both miR-30d
and siGALNT7, based on single color array data, were on
secondary modifications such as fucose and sialic acid as
well as terminal GalNAc, confirming a predominant effect on
O-linked glycosylation (Figure 5A). Importantly, cotransfection
of GALNT7 cDNA rescued these glycosylation defects for
both N- and O-linked glycans (Figure 5A; Figure S5A). To facil-
itate direct comparisons among samples, we utilized a moresensitive ratiometric two-color approach (Krishnamoorthy
et al., 2009) in which cell membrane micellae from scrambled-
transduced cells served as a common biological reference.
These data confirmed the observed general reduction in both
N- and O-linked glycosylation (Figure 5B; Figure S5B). Similar
but not completely overlapping changes were induced by
siGALNT1 (data not shown). That similar glycosylation changes
are induced by both miR-30d upregulation and siGALNT7,
and are restored by reexpressing GALNT7, support the key
contribution of GALNT7 repression to miR-30d-associated
phenotypes. It is likely that those modified glycosylation
patterns act as direct or indirect mediators of miR-30d’s prom-
etastatic role.
In order to determine the contribution of chemokine receptor
signaling to the prometastatic role of miR-30d, we investigated
the effects of blocking intracellular signaling by incubating
the melanoma cells with Pertussis toxin (PTX), which is known
to catalyze the ADP-ribosylation of the a subunits of the hetero-
trimeric G protein, and prevents Gi proteins from interacting
with G protein-coupled receptors on the cell membrane.Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc. 111
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Figure 6. miR-30d Promotes IL-10
Secretion by Suppressing GALNT7
(A) Levels of IL-10 in melanoma cells transduced
with miR-30d relative to scr control measured by
cytokine array. Quantification of signal density is
presented on the right.
(B) Levels of phosphorylation of proteins thatmight
explain the increase in IL-10 secretion from miR-
30d-transfected cells as measured by solid-phase
ELISA in indicated cell lines. Inset shows levels of
IL-10 secreted from the cells, quantified by ELISA
(mean ± SEM).
(C) Western blot of phospho-STAT3 levels in scr or
miR-30d-transfected cells. Tubulin served as
loading control.
(D) IL-10 mRNA levels in siGALNT7-transfected
melanoma cell lines 4L and 5B1 relative to scr
control as measured by qRT-PCR (mean ± SEM).
(E) Secretion of IL-10 to the supernatant of
siGALNT7-transfected or scr-transfected mela-
noma cell lines, as measured by ELISA.
(F) IL-10 mRNA (measured by qRT-PCR) levels
in indicated melanoma cells transfected with
scr, GALNT7 cDNA, or cotransfected with both
miR-30d and GALNT7 (mean ± SEM).
See also Figure S6.
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miR-30b/d Promote Metastasis by Targeting GALNT7Pretreatment of melanoma cells with PTX (100 ng/ml; 24 hr) had
little to no effect on miR-30d’s prometastatic potential in a tail
vein injection experiment (Figure S6). This suggests that Gi-
dependent chemokine signaling does not contribute significantly
to the effects ofmiR-30d or GALNT7 on extravasation, seeding,
or colonization, but we cannot rule out a Gi-independent chemo-
kine signaling.112 Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc.miR-30d Stimulates the Expression
of the Immunosuppressive
Cytokine Interleukin-10
by Repressing GALNT7
Our microarray analyses in two indepen-
dent cell lines revealed that miR-30d
ectopic expression results in mRNA
upregulation of some immune modula-
tors, among them the immunosup-
pressive immunoglobulin CTLA4 and the
immunosuppressive cytokine IL-10 (Fig-
ure 3A). Using human cytokine antibody
arrays and ELISA, we confirmed that
melanoma cells transfected with miR-
30d and 30b mimics secrete significantly
more IL-10 than scrambled controls
(Figures 6A and 6B; Figure S3D). In search
of a mechanism accounting for miR-
30d-mediated induction of IL-10, we
tested the effect of miR-30d on the
major signaling pathways known to
modulate IL-10 levels (i.e., PI3K, STAT3,
NF-kB, p38MAPK, JNK). Melanoma cells
that overexpress miR-30d displayed
increased levels of phospho-Tyr705-
STAT3 (Figures 6B and 6C), which isknown to transcriptionally activate IL-10 as well as numerous
prometastatic genes (Yu et al., 2009). Although STAT3 activation
could partially explain the elevated IL-10 expression, we asked
whether any of our identified miR-30d direct targets could
contribute to it. Surprisingly, we found that GALNT7 silencing is
sufficient to induce IL-10 synthesis and secretion to levels
comparable to those induced by miR-30d (Figures 6D and 6E)
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Figure 7. miR-30d Associates with Enhanced
Immunosuppressive Features at the Metastatic
Site
(A) Representative flow cytometry of Tregs (CD4+ CD25+
Foxp3+) isolated from whole lungs of mice injected with
B16F10/scr or B16F10/miR-30d (mean ± SEM). Isotype
controls are shown on the left for each treatment group.
See also Table S2.
(B) CD4 mRNA levels in macrometastases dissected from
B16F10/miR-30d relative to B16F10/scr-injected mice
(mean ± SEM).
(C) Foxp3 mRNA expression in macrodissected metas-
tases extracted from lungs of mice injected with B16F10/
miR-30d relative to B16F10/scr cells (mean ± SEM).
(D) CD3 immunofluorescence staining shows recruitment
of T cells to metastases of either B16F10/miR-30d or
B16F10/scr-injected mice. Corresponding H&E on con-
secutive sections are shown in upper panels, and meta-
static foci are circled. Scatter plot depicts the number of
recruited CD3+ T cells to the metastasis in several mice
per group. The number of recruited cells was normalized to
the area of metastasis.
(E) FoxP3 immunofluorescence staining shows recruit-
ment of regulatory T lymphocytes to B16F10/miR-30d
compared to B16F10/scr metastases. Corresponding
H&E on consecutive sections are shown in upper panels,
and metastatic foci are circled. Scatter plot depicts the
number of recruited CD3+ T cells to the metastasis in
several different mice for each group. Scale bars represent
100 mm (*p < 0.05; **p < 0.01).
See also Figure S7.
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miR-30b/d Promote Metastasis by Targeting GALNT7or miR-30b (Figure S3D), and that GALNT7 overexpression
counteracts miR-30d (Figure 6F) or miR-30b-mediated (Fig-
ure S3D) IL-10 upregulation. These results suggest that miR-
30d/30b induce IL-10 at least in part by repressing GALNT7,
revealing an unexpected role for a single GalNAc-T in linking
tumor cell invasion and immune modulation.Cancer Cell 20miR-30d Upregulation Triggers
Immunosuppressive Properties at the
Metastatic Site
To determine whether aberrantmiR-30d expres-
sion is able to promote an immunosuppressive
environment in vivo, we compared the recruit-
ment of T cells (CD3+), regulatory T cells
(Tregs; CD4+CD25+Foxp3+), activated dendritic
cells (DCs; MHCII+F480CD86+), and myeloid-
derived suppressor cells (MDSCs; CD11b+Gr1+)
to the lungs of immunocompetent mice injected
with B16F10/scr or B16F10/miR-30d cells
through the tail vein. FACS analysis showed
that lungs of B16F10/miR-30d-injected mice
contain significantly more Tregs (p = 0.03) (Fig-
ure 7A) than the equivalent scrambled controls,
with moderate changes in activated DCs and
no significant changes in MDSCs (Table S2).
Differences weremore prominent when individu-
ally macrodissected metastases were analyzed;
we noted that metastases from mice injected
with B16F10/miR-30d displayed lower local
levels of CD4 mRNA (p = 0.039) (Figure 7B) andhigher levels of Foxp3 mRNA (normalized to CD4 levels in the
tissue; p < 0.01) (Figure 7C) than those from mice injected with
B16F10/scr cells. Immunofluorescence stainings confirmed
both the reduction in T cell accrual (Figure 7D) and the increased
recruitment of Tregs to the metastases of B16F10/miR-30d cells
(Figure 7E). In accordance, immunohistochemistry analysis of, 104–118, July 12, 2011 ª2011 Elsevier Inc. 113
CD69
A B
C
GALNT7
CD69
CD
25
sc
r
30
d 
siG
AL
NT
7
siI
L-1
0
30
d+
siI
L-1
0
1.0
1.5
2.0
2.5
To
ta
l #
 o
f c
el
ls
/w
el
l (
x1
06
)
sc
r
30
d 
GA
LN
T7
30
d +
GA
LN
T7
0.0
0.5
1.0
To
ta
l #
 o
f c
el
ls
/w
el
l (
x1
06
)
D
CD
25
scr 30d siGALNT7 30d+siIL-10siIL-10
15.3% 2% 4.1% 13.7% 6.4%
49.5% 33% 41% 49.7%
scr 30d 30d+GALNT7
Figure 8. GALNT7 Modulation Accounts for miR-30d-Mediated Immunosuppressive Effects Ex Vivo
(A) FACS analysis of activated (CD25+CD69+ gated on CD4+) T lymphocytes isolated from spleens of Foxp3-GFPmice, stimulated by CD28 and CD3 antibodies,
and incubated for 72 hr in the presence of supernatants from A375 melanoma cells transfected with scr, miR-30d, siGALNT7, siIL10, and miR-30d+siIL-10.
(B) Total number of T cells at conclusion of the experiment (representative experiment, n = 3).
(C) FACS analysis of activated (CD25+CD69+ CD4+) T lymphocytes isolated from spleens of Foxp3-GFP mice, stimulated by CD28 and CD3 antibodies, and
incubated for 72 hr in the presence of supernatants from 5B1 melanoma cells transfected with scr+pCDNA3-Empty (scr), miR-30d+pCDNA3-Empty (30d),
scr+pCMV-GALNT7 (GALNT7), and miR-30d+pCMV-GALNT7 (30d+GALNT7).
(D) Total number of T cells at conclusion of the experiment (a representative experiment).
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miR-30b/d Promote Metastasis by Targeting GALNT7humanmetastaticmelanomas (n = 32) revealed some association
between miR-30d levels and FOXP3 expression in infil-
trating lymphocytes (p = 0.11; data not shown). Interestingly, we
found a significant correlation between FOXP3 expression and
miR-30d levels in the tumor cells themselves (n = 45; p = 0.02)
(Figure S7A). To confirm that FOXP3 is indeed expressed
by melanoma cells, we conducted HMBA-45 immunohistochem-
istry stainings in consecutive tissue sections (Figure S7B). Overall,
these results suggest thatmiR-30dmight contribute tometastasis
not only by promoting migration but also by suppressing immune
surveillance.
In order to explore the mechanism of immune modulation
by miR-30d, we tested the ability of miR-30d upregulation or
GALNT7 silencing to alter the secretion of immunomodulatory
molecules by melanoma cells. For that, CD4+ splenocytes iso-
lated from FoxP3-GFP mice (Bettelli et al., 2006) were activated
ex vivo with CD28 and CD3 antibodies and then incubated in
the presence of supernatants from scrambled, miR-30d, or
siGALNT7-transfected A375 melanoma cells. We observed
that supernatants from miR-30d or siGALNT7 cells display
increased ability to suppress T cell activation (assessed by
expression of surface markers CD25 and CD69) (Figure 8A),
and total T cell number (Figure 8B) than those from scrambled-
transfected cells. Importantly, these effects of miR-30d were
reversed by coexpression of GALNT7 cDNA in 5B1 melanoma
cells (Figures 8C and 8D). In addition, supernatants from miR-
30d and siGALNT7 promoted T cell differentiation into Tregs,114 Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc.as indicated by the number of CD25+ GFP+ (Foxp3+) cells (Fig-
ure S7C). Moreover, we found that concomitant silencing of IL-
10 by siRNA only partially counteractedmiR-30d’s immunosup-
pressive activities (Figures 8A and 8B; Figure S7C). Therefore,
our data suggest that IL-10 is one of multiple immunomodulatory
molecules in miR-30d’s regulated cellular secretome.
DISCUSSION
We have demonstrated that miR-30d/30b overexpression
enhances the invasive capacity of melanoma cells in vitro and
increases their metastatic potential in vivo, predominantly by
suppressing GALNT7. Downregulation of miR-30d produced
the opposite effects, whereas direct silencing of GALNT7 repli-
cated most effects of miR-30d/b overexpression. Changes in
glycosylation patterns have been associated with tumor
progression for some time (Dennis et al., 1999), yet the specific
molecular mechanisms underlying abnormal glycosylation and
the downstream processes directly or indirectly contributing to
metastasis remain poorly characterized. Strikingly, aberrant
miRNA-mediated regulation of a GalNAc-T promoted both cell
motility and immunosuppressive mechanisms, which could
synergize during metastasis.
Glycosylation in Tumor Progression
Our lectin arrays revealed that GALNT7 silencing or miR-30d
upregulation has specific effects on O-glycans and, to a lesser
Cancer Cell
miR-30b/d Promote Metastasis by Targeting GALNT7extent, on N-glycosylated substrates. Alterations in O-glycans
havemany biological consequences in cancer because potential
ligands responsible for interactions between cancer cells and
their microenvironment are changed. This influences the growth
and survival of the cell and its interactions with lectins and cell
surface receptors on neighboring cells or immune cells, all of
which are important for its ability to metastasize (Brockhausen,
2006). GalNAc-Ts initiate mucin-type O-linked glycosylation in
the Golgi apparatus by catalyzing the transfer of GalNAc to
serine and threonine residues on target proteins (Ten Hagen
et al., 2003). GalNAc-Ts have different but overlapping sub-
strate specificities and patterns of expression. Our glycomic
analysis revealed that GALNT7 silencing has broad effects on
the glycosylation of melanoma cells beyond its known trans-
ferase activity. These effects could be modulated through mis-
localization of other enzymes in the pathway due to loss of the
transferase or alterations in protein localization and stability
that influence the general glycosylation phenotype. Regardless,
the glycomic signature is clearly rescued by overexpression of
GALNT7, indicating that the effects are specific to this enzyme.
This modified glycocode might, at least partially, account for
miR-30d/siGALNT7 phenotype, even though the direct effectors
(i.e., proteoglycans, signaling pathways) of their proinvasive and
immunomodulatory actions could not be elucidated at this time.
Preincubation with PTX did not affect miR-30d’s prometastatic
effects, suggesting that Gi-dependent chemokine signaling is
not a key player, at least under those experimental conditions.
We have shown that expression of GALNT7 and GALNT1 is
controlled by miR-30b/30d levels, which increase during mela-
noma tumor progression in parallel with advancing stage and
metastatic potential at the time of diagnosis. Intriguingly, in addi-
tion to GALNT1 and GALNT7, other GalNAc-T family members
carry miR-30d recognition sites. We found that the expression
of many of them inversely correlated with miR-30d levels in
human samples, suggesting that this miRNA might coordinately
regulate the entire GALNT family. Not much is known about the
regulation of the GALNT family, though another miRNA, miR-
378, with a potential effect in osteoblast differentiation, was
shown to modulate GALNT7 (Kahai et al., 2009).
It is interesting to note that a prometastatic role for miR-30d
has also been recently shown in hepatocellular carcinoma (Yao
et al., 2010), and that miR-30d levels in the sera of patients
with lung cancer correlate with poor prognosis (Hu et al.,
2010). Together, these studies indicate that this miRNA cluster
(and possibly GALNT suppression) might exert a common prom-
etastatic effect in various cancers. Thus, the pleiotropic effects
(immunosuppressive and proinvasive) of miR-30d described
here for melanoma—mostly mediated by GalNAc-T suppres-
sion—might be relevant in other tumor types. In fact, metastatic
clones derived from colorectal cancer cells have altered ex-
pression of various GalNAc-Ts in comparison with their nonme-
tastatic parental counterparts (Kato et al., 2010).
Curiously, miR-30e, which shares a seed region with miR-
30b/d but is located in a separate genomic location, has shown
an antimetastatic role in breast cancer (Yu et al., 2010). A plau-
sible explanation for this apparent paradox is that whereas
O-glycosylation of specific substrates, particularly of mucins,
promotes breast or colon cancer progression (Brockhausen,
2006), the expression of mucins and their contribution to metas-tasis in melanoma are known to be limited (Bhavanandan, 1991).
In addition the cell type-specific repertoire of GalNAc-Ts, which
vary with cellular differentiation and malignant transformation
(Mandel et al., 1999), could account for the opposing outcomes
of miR-30e and miR-30b/30d induction in different tumors.
These observations underscore the context-dependence of
miRNA functions in cancer.
Although the prometastatic action of miR-30d is critically
mediated by GALNT7 silencing, we observed that GALNT7
ectopic expression did not completely counteract miR-30d’s
effects in vivo, suggesting a contribution of other miR-30d
targets. In fact, in addition to the GALNT family, we validated
othermiR-30d targets such as SEMA3A, which exerts antiangio-
genic functions (Maione et al., 2009; Serini et al., 2003), and
CESLR3 and TWF1, which are involved in cell-to-cell interactions
and migration. However, downregulation of these genes failed
to promote melanoma cell invasion through a fibronectin coat.
Nevertheless, they may mediate other metastatic abilities not
tested here, such as vascularization, adhesion, or motility. The
contributions of SEMA3A, CESLR3, and TWF1 to miR-30b/30d
prometastatic function need to be further investigated.
Immune Modulation in Melanoma
Melanoma is a paradigmatically immunogenic tumor, with abun-
dant inflammatory infiltrates in both cutaneous and metastatic
lesions, yet it manages to evade this upregulated host immune
response (Lee et al., 2005; Real et al., 2001; Redondo et al.,
2003). We found that miR-30d overexpression correlates with
reduced CD3+ T cell recruitment and accumulation of Tregs at
the metastatic site in vivo. Consistently, we demonstrated that
miR-30d upregulation alters melanoma cells’ secretome such
that it suppresses T cell activation and favors Treg induction
ex vivo. These effects can be partially mediated by increased
IL-10 secretion, which results from GALNT7 suppression. This
miR-30b/30d-GALNT7-IL-10 axis could provide a mechanistic
explanation for the immunosuppressive behavior of some meta-
static melanomas. We observed some association between
higher miR-30d expression and more FOXP3-positive lympho-
cytes (putative Tregs) in human metastatic samples. Surpris-
ingly, high 30d levels significantly correlated with FOXP3 expres-
sion in the tumor cells themselves. The expression of FOXP3 by
tumor cells was already reported in several cancer types (Hinz
et al., 2007; Merlo et al., 2009), including melanoma (Ebert
et al., 2008). It has been proposed that tumor cells expressing
FOXP3 share immunosuppressive effects with Tregs (Martin
et al., 2010), which might represent a new mechanism of im-
mune evasion in melanoma. Both cell and non-cell autonomous
mechanisms, potentially exerted by miR-30d, could cooperate
to restrain the host antitumoral response. miR-30d prometa-
static effects, critically mediated by GALNT7 suppression, are
prominent even in the absence of a functional host immune
system, as indicated by our experiments conducted in NOG/
SCID mice. However, our results in immunocompetent mice
reveal notable immunosuppressive effects associated with
miR-30d upregulation, which might synergize with its proinva-
sive properties during metastasis.
The control of immunostimulant or immunosuppressive mole-
cules by miRNAs in the context of tumor formation and progres-
sion is largely unexplored. miR-21, a miRNA with establishedCancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc. 115
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miR-30b/d Promote Metastasis by Targeting GALNT7tumorigenic role (Esquela-Kerscher and Slack, 2006), has been
shown to negatively regulate TLR4 via targeting the proinflam-
matory tumor suppressor PDCD4 (Sheedy et al., 2010), but to
our knowledge, the contribution of this mechanism to the
tumorigenic activities of miR-21 remains unknown. Evidence of
another miRNA directly targeting IL-10, miR-106a, has been
recently reported (Sharma et al., 2009). It is interesting to note
in this context that we found reduced miR-106a levels in
miR-30d-transduced cells (data not shown), which suggests
a possible miRNA network converging on the modulation of
IL-10 levels.
A recent report showed that Snail-mediated induction of
epithelial to mesenchymal transition induces an immunosup-
pressive response in melanoma cells mainly by inducing the
cytokine TSP1 (Kudo-Saito et al., 2009). These data and our
current results reveal that cell migration and immune evasion
are intimately connected during metastasis, and our findings
suggest that GalNAc-Ts can serve as a link between the two.
In sum this study shows that a single miRNA can exert both
proinvasive and immunomodulatory effects, and that both
actions could be critically mediated by one target, GALNT7.
Our data could have important prognostic implications: higher
miR-30d expression correlates with advanced melanoma and
aggressive biological behavior, and is a predictor of time to
death with melanoma, independent of thickness. Moreover,
miR-30d targeting represents a plausible therapeutic approach:
targeting miR-30d in tumor cells with chemically modified
oligonucleotides or artificial decoys (reviewed in Tong and
Nemunaitis, 2008; Valastyan and Weinberg, 2009) could dere-
press the endogenous GALNT7 levels, simultaneously counter-
acting both its proinvasive and immunosuppressive effects.
More research is needed to understand the effects of concur-
rently derepressing other miR-30d targets, but the possibility
remains that miRNA targeting could synergistically impede
metastasis as much as miRNA upregulation promotes it.
EXPERIMENTAL PROCEDURES
Cell Lines
Cell lines were cultured as previously described (Segura et al., 2009; Cruz-
Munoz et al., 2008). HEK293T and A375 cells were purchased from American
Type Culture Collection (ATCC). The B16F10 mouse melanoma cell line and
the humanWM35 andWM98 cell lines were acquired from theWistar Institute.
Cell lines 4L and 5B1 were isolated and cultured as previously described
(Cruz-Munoz et al., 2008). 4L, 5B1, A375, and B16F10 are metastatic mela-
noma cell lines, whereas WM35 and WM98 were derived from primary
melanomas.
Luciferase Assays
HEK293T cells were seeded into 96-well plates and cotransfected with
30UTR vectors and indicated amounts ofmiR-30b or -30dmimics or miRIDIAN
mimic negative control (Dharmacon). Luciferase activity was measured using
the Dual-Glo Luciferase Assay System (Promega). Renilla luciferase activity
was normalized to corresponding firefly luciferase activity and plotted as
a percentage of the control.
Ex Vivo T Cell Activation, Followed by FACS Analysis
CD4+ splenocytes were isolated from Foxp3-GFP mice using a CD4+ T Cell
Isolation Kit (Miltenyi Biotec). A total of 1 3 106 cells/24 wells were then incu-
bated in conditioned media of melanoma cells supplemented with 25 ml of
Dynabeads Human CD3/CD28 T-Cell Activator (Invitrogen). FACS analysis
was performed after 72 hr on cells stained for CD4 (APC-Cy7-conjugated;116 Cancer Cell 20, 104–118, July 12, 2011 ª2011 Elsevier Inc.BioLegend), CD25 (APC-conjugated; eBioscience), and CD69 (PE-conju-
gated; BD Biosciences).
Clinical Specimens
Human melanoma specimens (primary, metastatic) were collected at the
time of surgery. Approval to collect specimens was granted by New York
University Institutional Review Board protocol number 10362, ‘‘Development
of an NYU Interdisciplinary Melanoma Cooperative Group: A clinicopatholog-
ical database.’’ Informed consent was obtained from all subjects included.
Mouse Experiments
Experiments were conducted following protocols approved by the NYU
Institutional Animal Care Use Committee (IACUC) (protocol number 080109).
Statistical Methodologies
Statistical significance was determined by paired or unpaired Student’s t test
in cases of standardized expression data. One-way ANOVA was performed
for multiple group comparisons (GraphPad Prism Software). Wilcoxon
matched pairs test and Mann-Whitney U tests for nonparametric analyses
of non-Gaussian data. Chi-square test and McNemar’s test were used for
testing association among unmatched and matched categorical variables.
In particular, chi-square test and Fisher’s exact test were used to assess
association of miR-30d with FOXP3 staining in T cells and in melanoma cells
(Figure S7A). Multivariable COX PH models were used to analyze time-to-
recurrence and overall survival when adjusted for primary tumor thickness
and ulceration status. Log rank test was used for analyses presented in
Figures 1E and 1F.
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Coordinates have been deposited in the GEOArchive with accession code
GSE27718.
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